| Authors: |
O'Donnell P; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA. patricio.odonnell@sagerx.com.; McLean Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA, USA. patricio.odonnell@sagerx.com., Dong C; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Murthy V; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Asgharnejad M; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Du X; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA., Summerfelt A; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA., Lu H; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Xu L; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Wendland JR; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Dunayevich E; Neurocrine Biosciences, Inc., San Diego, CA, USA., Buhl DL; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA., Litman R; CBH Health, Gaithersburg, MD, USA., Hetrick WP; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA., Hong LE; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA., Rosen LB; Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA. |
